Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice†
Article first published online: 25 MAY 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 53, Issue 6, pages 1854–1863, June 2011
How to Cite
Hongthanakorn, C., Chotiyaputta, W., Oberhelman, K., Fontana, R. J., Marrero, J. A., Licari, T. and Lok, A. S. F. (2011), Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology, 53: 1854–1863. doi: 10.1002/hep.24318
Potential conflict of interest: R.J.F. did consulting/research for Bristol-Myers Squibb and GlaxoSmithKline, and was on the Speaker's Bureau for Gilead Sciences and Genentech. A.S.F.L. did consulting for Gilead Sciences, Roche, Bristol-Myers Squibb, and GlaxoSmithKline; and received grant/research support from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Schering-Plough, and Roche.
- Issue published online: 25 MAY 2011
- Article first published online: 25 MAY 2011
- Accepted manuscript online: 24 MAR 2011 08:45AM EST
- Manuscript Accepted: 15 MAR 2011
- Manuscript Received: 7 OCT 2010
Additional Supporting Information may be found in the online version of this article.
|HEP_24318_sm_suppinfotable1.doc||99K||Supporting Table 1. Outcomes of Patients Who Received Rescue Therapy|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.